Phantomics AI Platform
AI-powered cardiovascular health analysis and risk assessment platform
Platform · Cloud SaaSCompany source
Company profile
About Phantomics
Phantomics is a company operating in the cardiology and cardiovascular health sector, leveraging artificial intelligence and digital health technologies. Based on the limited information available, the company appears to be developing AI-driven solutions for cardiovascular care, though the specific nature of their products, target customers, and clinical applications remain unclear from the scraped content. The company maintains a web presence at phantomics.io with content available in multiple languages including English. Without access to detailed product information, company background, or mission statements from the About Us page content, the full scope of Phantomics' offerings and market position in the cardiovascular AI space cannot be comprehensively characterized at this time.
Company description Phantomics official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Phantomics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- cardiology
- cardiovascular disease
Who it serves
No customer types are currently listed.
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Enhanced risk stratification in hypertrophic cardiomyopathy through the integration of extracellular volume fraction on cardiovascular magnetic resonance.European heart journal. Cardiovascular Imaging · Jul 4, 2026
Prediction of Anthracycline-induced Cardiotoxicity Using Cardiac MRI Parameters: An Animal Study.Radiology. Cardiothoracic imaging · Jun 1, 2026
Development and validation of deep learning model for detection of obstructive coronary artery disease in patients with acute chest pain: a multi-center study.La Radiologia medica · Oct 1, 2025
Predicting Major Adverse Cardiac Events Using Deep Learning-based Coronary Artery Disease Analysis at CT Angiography.Radiology. Artificial intelligence · May 1, 2025
Automated extracellular volume fraction measurement for diagnosis and prognostication in patients with light-chain cardiac amyloidosis.PloS one · Jan 1, 2025
Validation of a deep learning-based software for automated analysis of T2 mapping in cardiac magnetic resonance imaging.Quantitative imaging in medicine and surgery · Oct 1, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
MyomicsK241922 · 510k · Feb 28, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Phantomics
Recent articles published on Phantomics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.